title: The road to purified hematopoietic stem cell transplants is paved with antibodies.
abstract: Hematopoietic progenitor cell replacement therapy remains a surprisingly unrefined process. In general, unmanipulated bone marrow or mobilized peripheral blood (MPB) grafts which carry potentially harmful passenger cells are administered after treating recipients with high-dose chemotherapy and/or radiotherapy to eradicate malignant disease, eliminate immunologic barriers to allogeneic cell engraftment, and to 'make space' for rare donor stem cells within the stem cell niche. The sequalae of such treatments are substantial, including direct organ toxicity and nonspecific inflammation that contribute to the development of graft-versus-host disease (GVHD) and poor immune reconstitution. Passenger tumor cells that contaminate autologous hematopoietic grafts may contribute to relapse post-transplant. Use of antibodies to rid grafts of unwanted cell populations, and to eliminate or minimize the need for nonspecifically cytotoxic therapies used to condition transplant recipients, will dramatically improve the safety profile of allogeneic and gene-modified autologous hematopoietic stem cell therapies.
authors.affiliation: Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, United States.
authors.forename: Aaron C
authors.initials: AC
authors.lastname: Logan
authors.forename: Irving L
authors.initials: IL
authors.lastname: Weissman
authors.forename: Judith A
authors.initials: JA
authors.lastname: Shizuru
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000378:metabolism / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology; D001666:Binding Sites, Antibody; D015815:Cell Adhesion Molecules / Q000276:immunology; D003888:Desensitization, Immunologic / Q000009:adverse effects / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D063268:Sialic Acid Binding Ig-like Lectin 3 / Q000276:immunology; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; C069847:CD66 antigens; D015815:Cell Adhesion Molecules; D063268:Sialic Acid Binding Ig-like Lectin 3